cms.bioaccessla.com

Blog

  • ZEED Pharmaceutical Solutions Mexico vs a First-in-Human Device CRO (bioaccess®)

    If you typed ZEED Pharmaceutical Solutions into a search box, you are probably building a CRO shortlist. This article uses only what ZEED Pharmaceutical Solutions publishes (zeed.com.mx) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What ZEED Pharmaceutical Solutions publishes

    ZEED Pharmaceutical Solutions is a Mexico City firm that plans and follows clinical research for new pharmaceutical products and medical devices. It emphasizes NOM-012, COFEPRIS and independent monitoring, and advertises Phase I PK, bioavailability and bioequivalence studies.

    ZEED Pharmaceutical Solutions vs bioaccess®

    Dimension ZEED Pharmaceutical Solutions bioaccess®
    Core focus Mexico BE / PK and independent monitoring First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If the need is independent monitoring or a bioequivalence package for COFEPRIS, ZEED fits.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including ZEED Pharmaceutical Solutions, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the ZEED Pharmaceutical Solutions public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Avant Santé Monterrey vs a First-in-Human Device CRO (bioaccess®)

    If you typed Avant Santé Research Center into a search box, you are probably building a CRO shortlist. This article uses only what Avant Santé Research Center publishes (www.avantsante.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Avant Santé Research Center publishes

    Avant Santé Research Center is based in San Pedro Garza García, Monterrey. It runs a Phase I unit for new chemical entities and BA/BE studies and promotes drug and device development on LinkedIn. Dr. Sitaramaraju Yarramraju is founder and CEO. Its device experience is less documented than its early-phase drug work.

    Avant Santé Research Center vs bioaccess®

    Dimension Avant Santé Research Center bioaccess®
    Core focus Mexico Phase I / BA-BE unit, drug-primary First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need a Mexican Phase I or bioequivalence unit for a drug, Avant Santé is a fit.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Avant Santé Research Center, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Avant Santé Research Center public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • EPIC Research CRO Mexico vs a First-in-Human Device CRO (bioaccess®)

    If you typed EPIC Research CRO into a search box, you are probably building a CRO shortlist. This article uses only what EPIC Research CRO publishes (epic-cro.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What EPIC Research CRO publishes

    EPIC Research CRO is based in Coyoacán, Mexico City. Its who-we-are page describes full-range clinical development, regulatory and post-approval services for the pharmaceutical, biotech, medical device and nutraceutical industries in Latin America. Annette G. Ortiz Austin is Director General.

    EPIC Research CRO vs bioaccess®

    Dimension EPIC Research CRO bioaccess®
    Core focus Mexico full-range CRO across product classes First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need Mexican clinical development plus post-approval support under one roof, EPIC publishes that menu.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including EPIC Research CRO, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the EPIC Research CRO public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • CREOS CRO Argentina vs a First-in-Human Device CRO (bioaccess®)

    If you typed CREOS into a search box, you are probably building a CRO shortlist. This article uses only what CREOS publishes (www.creoscro.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What CREOS publishes

    CREOS is a Buenos Aires CRO offering "solutions in clinical research to the pharmaceutical, biotechnology and medical devices industry": Phase I–III, bioequivalence, adaptive, basket and umbrella designs, and real-world evidence. Its co-founders are Daniel Livio, MD, and Néstor Flaster, MD, a former ANMAT evaluator.

    CREOS vs bioaccess®

    Dimension CREOS bioaccess®
    Core focus Argentine drug / RWE CRO with devices listed First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If the study is an Argentine Phase II–III, a bioequivalence study or a real-world evidence project, CREOS fits the brief.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including CREOS, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the CREOS public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Avanti Pesquisa Clínica Brazil vs a First-in-Human Device CRO (bioaccess®)

    If you typed Avanti Pesquisa Clínica into a search box, you are probably building a CRO shortlist. This article uses only what Avanti Pesquisa Clínica publishes (avantipc.com.br/en) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Avanti Pesquisa Clínica publishes

    Avanti Pesquisa Clínica is a São Paulo ARO/CRO that serves pharmaceutical, biotechnology, biosimilar and medical device companies across Phases I–IV, with clinical supplies and device storage among its services. We found no named device study on its site.

    Avanti Pesquisa Clínica vs bioaccess®

    Dimension Avanti Pesquisa Clínica bioaccess®
    Core focus Brazil ARO/CRO + clinical supplies First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need a Brazilian partner for study execution plus clinical-supply logistics, Avanti covers both.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Avanti Pesquisa Clínica, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Avanti Pesquisa Clínica public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Azidus / AZD CRO Brazil vs a First-in-Human Device CRO (bioaccess®)

    If you typed Azidus (AZD CRO) into a search box, you are probably building a CRO shortlist. This article uses only what Azidus (AZD CRO) publishes (azidusbrasil.com.br) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Azidus (AZD CRO) publishes

    Azidus Brasil (AZD CRO) is based in Valinhos, São Paulo state, with partnerships it lists across Latin America, North America, Israel and Eastern Europe. It offers First in Human, proof-of-concept and Phase I work, and its solutions cover health products alongside synthetics, biologics, cell therapy, vaccines, cosmetics and food. Dra. Luciana Ferrara is CEO. Its client list is mostly pharma.

    Azidus (AZD CRO) vs bioaccess®

    Dimension Azidus (AZD CRO) bioaccess®
    Core focus Brazil early-phase CRO, drug and health products First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need Brazilian Phase I or proof-of-concept for a drug, biologic or cosmetic, Azidus is built for that.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Azidus (AZD CRO), for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Azidus (AZD CRO) public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Intrials Brazil CRO vs a First-in-Human Device CRO (bioaccess®)

    If you typed Intrials into a search box, you are probably building a CRO shortlist. This article uses only what Intrials publishes (intrials.com.br) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Intrials publishes

    Intrials is a São Paulo CRO founded in 1999, operating in Brazil, Argentina, Chile, Colombia, Mexico and Peru. It runs Phase I–IV with core areas in oncology, infectious disease and vaccines, rare disease, immunology, cardiology, dermatology and respiratory, and a Medidata partner listing includes devices and diagnostics. Sergio Braga Filho is President and CEO. We found no named device first-in-human study.

    Intrials vs bioaccess®

    Dimension Intrials bioaccess®
    Core focus Homegrown full-service LATAM CRO, drug-primary First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If the program is a multi-country Phase II–III drug or late-phase study across South America and Mexico, Intrials is a strong homegrown option.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Intrials, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Intrials public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Elemental / CORVIA CRO Mexico vs a First-in-Human Device CRO (bioaccess®)

    If you typed CORVIA CRO / Elemental consortium into a search box, you are probably building a CRO shortlist. This article uses only what CORVIA CRO / Elemental consortium publishes (elemental.org.mx/cro · elemental.org.mx/consorcio) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What CORVIA CRO / Elemental consortium publishes

    Elemental is a Mexican consortium whose CRO page offers services for pharmaceuticals, biotech products, supplements and medical devices. Its consortium sites include CECyPE in Morelia, IDEAS / IDeCSa in Mexico City, CIMET in Guadalajara and FScientia in San Luis Potosí. It also lists prototype development and medical-device protocol design. We found no named device first-in-human study.

    CORVIA CRO / Elemental consortium vs bioaccess®

    Dimension CORVIA CRO / Elemental consortium bioaccess®
    Core focus Mexican site consortium + CRO across product classes First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you want Mexican site capacity across several cities and a group that also helps with prototype development, Elemental is worth a call.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including CORVIA CRO / Elemental consortium, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the CORVIA CRO / Elemental consortium public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Infinite Clinical Research Mexico vs a First-in-Human Device CRO (bioaccess®)

    If you typed Infinite Clinical Research (WEAREINFINITE) into a search box, you are probably building a CRO shortlist. This article uses only what Infinite Clinical Research (WEAREINFINITE) publishes (weareinfinite.mx) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Infinite Clinical Research (WEAREINFINITE) publishes

    Infinite Clinical Research (WEAREINFINITE) is a Mexico City CRO that calls itself "100% Mexican" and full-service, and is a founding member of ACROM. It publishes a research protocols and medical devices service, COFEPRIS device registrations and technovigilance. We found no named device protocol or sponsor on its site.

    Infinite Clinical Research (WEAREINFINITE) vs bioaccess®

    Dimension Infinite Clinical Research (WEAREINFINITE) bioaccess®
    Core focus Mexico full-service CRO with device protocols and COFEPRIS First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If Mexico is the only country and you want one local firm for the protocol and the COFEPRIS registration, Infinite publishes both.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Infinite Clinical Research (WEAREINFINITE), for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the Infinite Clinical Research (WEAREINFINITE) public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • MSC MED Brazil Device CRO vs a First-in-Human CRO for Latin America (bioaccess®)

    If you typed MSC MED into a search box, you are probably building a CRO shortlist. This article uses only what MSC MED publishes (www.mscmed.com.br/en) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What MSC MED publishes

    MSC MED (MSc Med Engenharia e Tecnologia Médica Ltda.) is a Brazilian CRO headquartered in Florianópolis with a commercial office in Curitiba. It describes itself as a CRO specializing in safety and efficacy demonstration and international regulation of medical devices. Services include clinical evaluation (ISO / ANVISA), biocompatibility, MRI compatibility and registration hosting. Heitor Korndorfer is founder and CEO.

    MSC MED vs bioaccess®

    Dimension MSC MED bioaccess®
    Core focus Device clinical evaluation, testing and Brazil regulatory First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If the job is clinical evaluation, biocompatibility or MRI-compatibility work, or a Brazil registration, MSC MED is built for it.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including MSC MED, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the MSC MED public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.